Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer.

Hypoxia (Auckl) · 2016 · PMC5153268 · PMID 27995152

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

Extent of Bcl-2 inhibition in sorafenib combination with GDC-0941 was comparable under hypoxia and normoxia, indicating that these proteins may not be significant in influencing the outcome of combinations under hypoxia.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.